Semaglutide --- Weight Loss Drug
Studies have shown that overweight/obese diabetic patients lose 5% to 10% of their weight, blood pressure, blood sugar, low-density lipoprotein cholesterol, and triglycerides can be reduced, high-density lipoprotein cholesterol increases, and the cardiovascular risk of patients decreases.
For drug weight loss, the US FDA has approved 5 types of weight loss drugs, including liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) analog, which not only lowers blood sugar, but also has cardiovascular protection.
Large-scale clinical studies such as LEADER and SUSTAIN-6 have proved that this type of drug can significantly reduce the weight and cardiovascular risk of diabetic patients.
Recently, the STEP-2 trial also found that patients with type 2 diabetes who injected semaglutide weekly lost an average weight of about 20 catties.
Studies have shown that two-thirds of patients with type 2 diabetes lost at least 5% of their body weight and significantly improved their blood sugar control levels when given weekly injections of 2.4 mg of semaglutide.
In addition, more than a quarter of patients lost 15 percent of their body weight. This weight loss effect exceeds that of any current hypoglycemic drug.
The researchers believe that semaglutide has opened a new era of weight management for patients with type 2 diabetes, marking a change in the treatment of obesity, and the weight loss effect is close to bariatric surgery.
In addition to weight loss, the patient's overall health status improved, and physical function scores, blood pressure, and blood sugar all improved significantly.
The study, called STEP-2, was conducted in 149 centers in 12 countries and regions around the world, and included 1,210 patients with type 2 diabetes. These participants had an average disease duration of up to 8 years, poor glycemic control (glycosylated hemoglobin 7% to 10%), and an average body mass index of 35.7 kg/m2. Semaglutide was injected subcutaneously once a week for 68 weeks.
The STEP series of studies have shown that 68 weeks of semaglutide treatment, combined with lifestyle intervention, can help patients lose an average of 20-34 catties.
It is reported that in view of STEP research, Novo Nordisk, the manufacturer of semaglutide, submitted a marketing authorization in the United States in December 2020, hoping that semaglutide (2.4 mg) can be used to treat patients with at least one weight-related combination. adults who are obese or overweight.
Any other questions, just contact us freely via email: info@haozbio.com
